Beam Therapeutics Inc.
BEAMNext catalyst
BEAM-201
Lymphoblastic Lymphoma
Get an email about BEAM's next catalysts
Track Beam Therapeutics (BEAM) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
BEAM Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-1.16 | FQ end Sep/2026 | Call: tbd
BEAM-201 Phase 2 Est. Readout
Primary completion for BEAM-201 trial (NCT05885464) in Lymphoblastic Lymphoma
SourceMarket Overview
Stock performance and key metrics
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.
WebsiteBEAM-101
Sickle Cell Disease
BEAM-201
Lymphoblastic Lymphoma
BEAM-301: Single dose of BEAM-301 administered by IV
Glycogen Storage Disease Type Ia
BEAM-302
Alpha 1-Antitrypsin Deficiency
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BEAM-101 | Phase 2 | Sickle Cell Disease | - | - |
BEAM-201 | Phase 2 | Lymphoblastic Lymphoma | - | - |
BEAM-301: Single dose of BEAM-301 administered by IV | Phase 2 | Glycogen Storage Disease Type Ia | - | - |
BEAM-302 | Phase 2 | Alpha 1-Antitrypsin Deficiency | - | - |
Sickle Cell Disease
1 drug in this indication
Lymphoblastic Lymphoma
1 drug in this indication
Glycogen Storage Disease Type Ia
1 drug in this indication
Alpha 1-Antitrypsin Deficiency
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Beam Therapeutics Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Beam Therapeutics Inc.'s (BEAM) pipeline across Phase 2. Its lead program is BEAM-201 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Beam Therapeutics Inc.'s next FDA catalyst?→
Beam Therapeutics Inc.'s (BEAM) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BEAM biotech catalysts?→
Add BEAM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Beam Therapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.